Dasatinib: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
PHARMAC (New Zealand) and TLV (Sweden) recommended or restricted dasatinib, while CONITEC (Brazil) did not recommend it.
The file has been open for more than a decade: 16.3 years separate the first record, 6 Mar 2007 at TLV (Sweden), from the most recent, 2023 at PBAC (Australia).
SMC (Scotland) changed its position: not recommended on 7 May 2007, recommended by 8 Apr 2019, after a resubmission.
No assessment is on file from CIPM (Spain) and G-BA (Germany), each among the eight highest-volume agencies here.
Not every gap is a refusal: for dasatinib, 1 submission was never made and 1 was withdrawn or terminated before a decision — an outcome set by the company rather than the assessor.
The programme is broad: 12 distinct indication wordings are recorded for dasatinib by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
4 of these 27 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
TLV (Sweden) was first to assess dasatinib, on 6 Mar 2007; NICE (England) did not open a file until 14 Jul 2021 — an unusually long tail of 14.3 years between the earliest and latest system to look at it.
The record arrives in waves: 5 separate years each carry two or more decisions, spread across 12 years in total.
5 of the 8 agencies here assessed dasatinib more than once, HAS (France) most often at 7 entries — repeat review is the norm for this molecule rather than the exception.
8 of the 18 agencies in this archive hold a record for dasatinib.
The full ledger for dasatinib reads 13 recommended, 5 not recommended, 3 superseded and 3 other, with 3 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| PBAC (Australia) | 2023 | Tyrosine kinase inhibitors (TKIs) for Philadelphia chromosome positive (Ph+) acute lymphoblastic leukaemia (ALL) | Recommended | source |
| NICE (England) | 14 Jul 2021 | NICE TA714 | terminated appraisal | source |
| CONITEC (Brazil) | 31 Dec 2020 | Adultos com leucemia linfoblástica aguda cromossomo Philadelphia positivo (LLAPh+) resistentes/intolerantes ao mesilato … | not incorporated | source |
| AWMSG (Wales) | 19 Jan 2012 | Treatment of adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukaemia in… | superseded (full) | source |
| HAS (France) | 5 Jan 2011 | Listing (Transparency Committee) | ASMR V | source |
22 further decisions for dasatinib, across 6 agencies, are not shown here. They link to 16 further source documents.
Related molecules
- imatinib — divergent outcome (recommended vs other) on a shared indication
- nilotinib — divergent outcome (recommended vs not recommended) on a shared indication
- ibrutinib — same ATC class L01E — Antineoplastics
- zanubrutinib — same ATC class L01E — Antineoplastics
- cabozantinib — same ATC class L01E — Antineoplastics
- selpercatinib — same ATC class L01E — Antineoplastics
Coverage: 27 decisions for dasatinib from 8 agencies, 2007 to 2023. Data to 7 Sep 2026. ATC class L01E — Antineoplastics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.